The Valley Desk

ArticleNew microbes and new infectionsPublished

An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name GSK, Hospital of the University of Pennsylvania, with Penn Medicine linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
New microbes and new infections
Published
Subject terms
Monoclonal antibodies; Immunocompromised host; Pre-exposure Prophylaxis; Covid-19
PubMed ID
40893477
PubMed Central ID
PMC12395066
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal